What is the role of dipyridamole (Persantine) in the treatment of hypercalciuria?

Updated: Jun 02, 2021
  • Author: Stephen W Leslie, MD, FACS; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Dipyridamole (Persantine) is a platelet adhesion inhibitor and vasodilator. It is usually used to lengthen platelet survival time and reduce the incidence of thromboembolic phenomenon after heart valve replacement surgery. Researchers have found that dipyridamole reduces renal phosphate excretion, which increases the serum phosphate level, resulting in decreased activation of vitamin D3 and then in reduced hypercalciuria. This is useful in patients with vitamin D–dependent hypercalciuria, such as the renal phosphate leak (absorptive hypercalciuria type III) form, especially when orthophosphates are not tolerated or cannot be used.

No direct effect on urinary calcium excretion is present. Adverse effects are minimal, but the medication must be taken frequently. Dipyridamole has been shown to reduce urinary calcium excretion in patients with vitamin D–dependent renal phosphate leak on a long-term basis. [47, 48]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!